Mould DR - Search Results

1

Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Melmed GY, et al. Among authors: mould dr. Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14. Clin Gastroenterol Hepatol. 2016. PMID: 27189916

2

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.

Ordás I, Mould DR, Feagan BG, Sandborn WJ. Ordás I, et al. Among authors: mould dr. Clin Pharmacol Ther. 2012 Apr;91(4):635-46. doi: 10.1038/clpt.2011.328. Epub 2012 Feb 22. Clin Pharmacol Ther. 2012. PMID: 22357456 Review.

3

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.

Mould DR, Dubinsky MC. Mould DR, et al. J Clin Pharmacol. 2015 Mar;55 Suppl 3:S51-9. doi: 10.1002/jcph.370. J Clin Pharmacol. 2015. PMID: 25707964 Review.

4

Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.

Dubinsky MC, Phan BL, Singh N, Rabizadeh S, Mould DR. Dubinsky MC, et al. Among authors: mould dr. AAPS J. 2017 Jan;19(1):215-222. doi: 10.1208/s12248-016-9994-y. Epub 2016 Oct 13. AAPS J. 2017. PMID: 27739008

5

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.

Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Vande Casteele N, et al. Among authors: mould dr. Clin Pharmacokinet. 2017 Dec;56(12):1513-1523. doi: 10.1007/s40262-017-0535-3. Clin Pharmacokinet. 2017. PMID: 28353055

6

Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming.

Mould DR, Upton RN, Wojciechowski J, Phan BL, Tse S, Dubinsky MC. Mould DR, et al. AAPS J. 2018 Jun 14;20(4):76. doi: 10.1208/s12248-018-0237-2. AAPS J. 2018. PMID: 29904814 Review.

7

Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.

Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Turner D, et al. Among authors: mould dr. Gut. 2020 Jan;69(1):32-41. doi: 10.1136/gutjnl-2018-317987. Epub 2019 Apr 12. Gut. 2020. PMID: 30979718 Free article.

8

Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.

Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dubinsky MC, et al. Among authors: mould dr. Inflamm Bowel Dis. 2022 Sep 1;28(9):1375-1385. doi: 10.1093/ibd/izab285. Inflamm Bowel Dis. 2022. PMID: 34978325 Clinical Trial.

9

Application of a Precision-Dosing Model to a Real-World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis.

Nguyen AL, Gibson PR, Upton RN, Mould DR, Sparrow MP. Nguyen AL, et al. Among authors: mould dr. J Clin Pharmacol. 2024 Apr;64(4):399-409. doi: 10.1002/jcph.2384. Epub 2023 Dec 3. J Clin Pharmacol. 2024. PMID: 37964618

10

Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.

Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, Ben Yehoyada M, Mould DR. Dotan I, et al. Among authors: mould dr. Inflamm Bowel Dis. 2014 Dec;20(12):2247-59. doi: 10.1097/MIB.0000000000000212. Inflamm Bowel Dis. 2014. PMID: 25358062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters